Biotech News & Trading Forum: Community User: Weedmaster

Danke Ali3n für deine Einschätzung. Ich wollte demnächst wieder einsteigen und auf den gleichen Hype wie letztes Jahr spekulieren. Diese Veränderung ist aber leider nicht planbar... mal schauen

@Sebastian_383, ich weiß auch nicht wirklich was ich davon halten soll, allerdings denke ich, dass die die CF pipe dann hoffentlich zu den 100% verkaufen, denn das BoD hat ja auch massig Aktien von PTI. Aber unterm Strich, werd ich mal halten, denn ein Mittel gegen Alzheimer wie auch eines gegen Parkinson, dauert zwar in der Entwicklung, aber bei jeder neuen Phase legt das Unternehmen bei positiven Ergebnissen (vorausgesetzt) ordentliche Sprünge nach oben hin. Mal sehn was raus kommt.

https://www.vbivaccines.com/wire/preclinical-coronavirus-data-candidate-selection/

Was haltet ihr aktuell von Proteostasis insbesondere zum geplanten Merger? Leider findet man wenig über Yumanity Therapeutics.

Kurz feucht gewischt. Soll ja biologisch bleiben. 😉

Miragen Therapeutics MGEN Progress on next generation microRNA-29 mimic for use in pulmonary fibrosis (MRG-229) includes new preclinical data; additional NIH grant funding triggered Exploratory preclinical safety and pharmacokinetic data for MRG-229 expected before year end Plan to receive guidance from the FDA on proposed regulatory pathway for cobomarsen in ATLL before year end A majority of patients in the Phase 2 SOLAR trial of cobomarsen in CTCL have continued to receive uninterrupted treatment and are being evaluated for clinical response Reported $30.6 million in cash and cash equivalents as of June 30, 2020; anticipate cash runway into Q3 2021

Co-Diagnostics Reports Q2 Sales Increased By 1,503% To $24M Driven By Its COVID-19 Tests Benzinga · 25.8.2020, 12:38:10

Will Lipocine Succeed With Its Fourth Try? Company: Lipocine Inc (NASDAQ: LPCN) Type of Application: NDA Candidate: Tlando Indication: Hypogonadism Date: Aug. 28 Tlando, a novel oral prodrug of testosterone containing testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal men. The investigational asset stumbled at the FDA altar three times in the past. Following Lipocine's third resubmission, the FDA has established a PDUFA action date of Aug. 28 Roche Hopes To Be Better Late Than Never Company: Roche Type of Application: BLA Candidate: Satralizumab Indication: neuromyelitis optica spectrum disorder, or NMOSD Date: Aug. 29 Satralizumab is an investigational humanized monoclonal antibody that targets the IL-6 receptor. The cytokine IL-6 is thought to be a key driver of NMOSD, triggering the inflammation cascade and leading to damage and disability. Roche announced FDA acceptance of the BLA Oct. 30, and assuming a standard ten-month review period, the decision is expected Aug. 29. Earlier this year, the Japanese drug regulatory agency approved satralizumab for treating NMOSD. If the approval comes through, Roche may have to face competition from two drugs already in the market, namely Alexion Pharmaceuticals, Inc.'s (NASDAQ: ALXN) Soliris and Viela Bio Inc's (NASDAQ: VIE) Uplizna. Morphosys-Incyte Await FDA Word On Lymphoma Drug Company: Incyte Corporation(NASDAQ: INCY) and Morphosys Ag (NASDAQ: MOR) Type of Application: BLA Candidate: Tafasitamab Indication: diffuse large B cell lymphoma, or DLBCL Date: Aug. 30 Tafasitamab is an investigational humanized Fc-engineered monoclonal antibody directed against CD19. Morphosys had licensed the investigational asset from Xencor Inc (NASDAQ: XNCR) in 2010. In January, Morphosys and Incyte entered into a a collaboration and licensing agreement to commercialize tafasitamab globally. The FDA accepted March 2, Morphosys' BLA, seeking approval for tafasitamab, in combination with Revlimid, as a treatment option for relapsed or refractory DLBCL. The agency set a PDUFA action date of Aug. 30.

Glaub Weed muss mal durchwischen 🤦‍♂️

http://stocktwits.com/Zonic/message/238797191

CODX ist interessant. RSI zeigt überverkauft an. Mal eine Position reingeholt.

https://www.benzinga.com/pressreleases/20/08/g17205445/trevena-announces-initiation-of-trv027-study-in-covid-19-patients-in-collaboration-with-imperial-c